Alexander Lu

University of California System — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

6h-index318citations72works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(48), Multiple Myeloma Research and Treatments(36), Peptidase Inhibition and Analysis(20), Cancer, Lipids, and Metabolism(19), Chemokine receptors and signaling(18)

Publications72 total

Dynamic Kinetic Asymmetric Hydroacylation: Racemization by Soft Enolization
Journal of the American Chemical Society·2025· 4 citedOpen Access
Figure S9 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Table S6 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Figure S13 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
FIGURE 5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Table S5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
FIGURE 3 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Data from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Table S9 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
FIGURE 2 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Table S3 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
FIGURE 7 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Figure S5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Table S1 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Figure S12 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
FIGURE 1 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Figure S1 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Figure S9 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Figure S7 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Figure S10 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Vy M. Dong(48), Dennis Juarez(41), Roberta Buono(41), Shannon M. Matulis(41), Vikas A. Gupta(41), Madeleine Duong(41), Jacob Yudiono(41), Madhuri Paul(41), Sharmila Mallya(41), Grace Diep(41), Peter Hsin(41), Sang Mi Suh(41), Andrew W. Roberts(41), Joel Johansson(41), Muhammad Jalaluddin(41), Zhuangzhuang Liu(41), Orlando F. Bueno(41), Lawrence Boise(41), Roberta Buono(41), Shao‐Zhen Nie(2)